An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer

Medicine & Life Sciences

• Anti-Idiotypic Antibodies 42%
• Bevacizumab 55%
• Cell Membrane 4%
• Clinical Trials 3%
• Disease Progression 4%
• Endoglin 71%
• Endothelial Cells 4%
• Glioblastoma 5%
• Headache 4%
• Hepatocellular Carcinoma 4%
• Hypertension 3%
• Immunoglobulin G 4%
• Monoclonal Antibodies 4%
• Neoplasms 16%
• Pharmacokinetics 4%
• Population 2%
• Protein-Tyrosine Kinases 5%
• Proteinuria 5%
• Renal Cell Carcinoma 5%
• Research Design 4%
• Response Evaluation Criteria in Solid Tumors 7%
• Safety 3%
• Sarcoma 5%
• Therapeutics 1%
• TRC105 100%
• Tumor Burden 5%
• Vascular Endothelial Growth Factor A 19%
• Vascular Endothelial Growth Factor Receptor 6%